Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Interim Phase IIa data positive for Raptor's liver drug
13 October 2009
Asher Mullard

asher.mullard@informa.com

Raptor Pharmaceuticals' DR Cysteamine (delayed release cysteamine bitartrate) met its primary efficacy endpoint in patients with non-alcoholic steatohepatitis (NASH), show interim data. The announcement on October 12th sent the company's shares up nearly 30%, to close at $4.30 on Nasdaq.

"These...



Please Login to read the full article.
 
Not a subscriber? Subscribe to Scrip Request a FREE Trial
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Other Informa Analysis
COMMENT Other Informa Comment
FEATURES Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm